Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025
Philips (NYSE:PHG) unveiled innovative CT and MR solutions for radiation therapy at ASTRO 2025. The company introduced two new CT platforms - Rembra RT and Areta RT - featuring ultra-fast image reconstruction speeds of up to 106 images per second and an extended 85cm field of view.
Additionally, Philips debuted the helium-free BlueSeal RT 1.5T 70cm MR system in North America, powered by AI-based SmartSpeed Precise acceleration software. The system enables MR-only simulation protocols in as little as 10 minutes and features a lightweight, vent-pipe-free design for flexible installation options.
Both innovations aim to enhance radiation therapy planning with improved accuracy, efficiency, and sustainability while reducing operational costs and improving patient experience.
Philips (NYSE:PHG) ha presentato soluzioni innovative di CT e RM per la radioterapia a ASTRO 2025. L'azienda ha introdotto due nuove piattaforme CT - Rembra RT e Areta RT - caratterizzate da velocità di ricostruzione delle immagini ultra-rapide fino a 106 immagini al secondo e da un campo di vista esteso di 85 cm. Inoltre Philips ha presentato nel Nord America il sistema RM BlueSeal RT 1.5T 70cm senza elio, alimentato dal software di accelerazione SmartSpeed Precise basato sull'IA. Il sistema consente protocolli di simulazione MR-only in appena 10 minuti e presenta un design leggero, senza tubi di ventilazione, per opzioni di installazione flessibili. Entrambe le innovazioni mirano a migliorare la pianificazione della radioterapia con maggiore precisione, efficienza e sostenibilità, riducendo i costi operativi e migliorando l'esperienza del paziente.
Philips (NYSE:PHG) presentó soluciones innovadoras de TC y RM para la radioterapia en ASTRO 2025. La compañía introdujo dos nuevas plataformas de TC: Rembra RT y Areta RT, con velocidades de reconstrucción de imágenes ultrarrápidas de hasta 106 imágenes por segundo y un campo de visión ampliado de 85 cm. Además, Philips presentó en Norteamérica el sistema de RM BlueSeal RT 1.5T 70cm sin helio, impulsado por el software de aceleración basado en IA SmartSpeed Precise. El sistema habilita protocolos de simulación MR-only en apenas 10 minutos y cuenta con un diseño ligero, sin tubos de ventilación, para opciones de instalación flexibles. Ambas innovaciones buscan mejorar la planificación de la radioterapia con mayor precisión, eficiencia y sostenibilidad, reduciendo los costos operativos y mejorando la experiencia del paciente.
필립스(NYSE:PHG)는 ASTRO 2025에서 방사선 치료를 위한 혁신적인 CT 및 MR 솔루션을 공개했습니다. 회사는 Rembra RT와 Areta RT라는 두 가지 새로운 CT 플랫폼을 도입했으며, 초고속 이미지 재구성 속도는 초당 최대 106이미지, 확장된 시야(FOV) 85cm를 자랑합니다. 또한 북미에서 헬륨 무게의 BlueSeal RT 1.5T 70cm MR 시스템을 발표했고, AI 기반의 소프트웨어 SmartSpeed Precise 가속을 지원합니다. 이 시스템은 MR-only 시뮬레이션 프로토콜을 단 10분 만에 가능하게 하며, 경량의 환기 파이프 없는 설계로 설치 옵션의 융통성을 제공합니다. 두 혁신은 정확도, 효율성 및 지속 가능성을 높이고 운영 비용을 낮추며 환자 경험을 개선하는 방사선 치료 계획을 목표로 합니다.
Philips (NYSE:PHG) a dévoilé des solutions innovantes de CT et RM pour la radiothérapie lors de l’ASTRO 2025. La société a présenté deux nouvelles plateformes CT – Rembra RT et Areta RT – avec des vitesses de reconstruction d’images ultra-rapides allant jusqu’à 106 images par seconde et un champ de vision élargi à 85 cm. Le système MR sans déploiement d’hélium BlueSeal RT 1.5T 70 cm est également annoncé en Amérique du Nord, propulsé par le logiciel d’accélération basé sur l’IA SmartSpeed Precise. Le système permet des protocoles de simulation MR-only en seulement 10 minutes et présente un design léger, sans conduits d’aération, offrant des options d’installation flexibles. Ces deux innovations visent à améliorer la planification de la radiothérapie par une meilleure précision, efficacité et durabilité, tout en réduisant les coûts opérationnels et en améliorant l’expérience des patients.
Philips (NYSE:PHG) stellte auf der ASTRO 2025 innovative CT- und MR-Lösungen für die Strahlentherapie vor. Das Unternehmen führte zwei neue CT-Plattformen ein – Rembra RT und Areta RT – mit extrem schnellen Bildrekonstruktionsgeschwindigkeiten von bis zu 106 Bildern pro Sekunde und einem erweiterten Sehfeld von 85 cm. Zudem präsentierte Philips in Nordamerika das helium-freie MR-System BlueSeal RT 1.5T 70 cm mit KI-basierter Beschleunigungssoftware SmartSpeed Precise. Das System ermöglicht MR-only-Simulationsprotokolle in nur 10 Minuten und verfügt über ein leichtes, vent-pipe-freies Design für flexible Installationsoptionen. Beide Innovationen zielen darauf ab, die Planung der Strahlentherapie durch verbesserte Genauigkeit, Effizienz und Nachhaltigkeit zu optimieren, während Betriebskosten gesenkt und die Patientenerfahrung verbessert werden.
كشفت Philips (NYSE:PHG) عن حلول CT وMR مبتكرة للعلاج الإشعاعي في ASTRO 2025. قدمت الشركة منصتين جديدتين للـCT - Rembra RT و Areta RT - بسرعة إعادة بناء صور فائقة تصل إلى 106 صورة/ثانية ونطاق رؤية موسع يبلغ 85 سم. كما كشفت Philips عن نظام MR BlueSeal RT 1.5T 70cm بدون هيلوم في شمال أمريكا، يعمل ببرمجية التسريع القائمة على الذكاء الاصطناعي SmartSpeed Precise. يتيح النظام بروتوكولات محاكاة MR-only في غضون 10 دقائق فقط ويتميز بتصميم خفيف الوزن وخال من أنابيب التهوية لتوفير خيارات تثبيت مرنة. كلا الابتكارين يهدفان إلى تحسين تخطيط العلاج الإشعاعي من خلال زيادة الدقة والكفاءة والاستدامة مع خفض تكاليف التشغيل وتحسين تجربة المريض.
飞利浦（NYSE:PHG）在ASTRO 2025上推出用于放射治疗的创新CT与MR解决方案。公司推出了两款新的CT平台——Rembra RT与Areta RT——其图像重建速度高达每秒106张，视野扩展至85厘米。此外，飞利浦在北美推出无helium的BlueSeal RT 1.5T 70cm MR系统，由基于人工智能的加速软件SmartSpeed Precise驱动。该系统使MR-only仿真协议在10分钟内完成，并具备轻量、无通风管的设计，为安装提供灵活选项。两项创新旨在通过提升准确性、效率与可持续性来优化放射治疗计划，同时降低运营成本并提升患者体验。
- New CT platforms offer ultra-fast image reconstruction speeds of 106 images/second
- Tube for Life Guarantee and potential 20-year service life reduce long-term costs
- Helium-free MR system design reduces operational costs and energy consumption
- 91% of care teams report improved workflow efficiency with new touchscreen controls
- Rembra RT and Areta RT platforms are pending 510(k) clearance, not yet available for sale in US
Insights
Philips expands radiation oncology portfolio with innovative CT/MR systems focused on precision, efficiency, and sustainability, strengthening market position.
Philips has strategically expanded its radiation oncology imaging portfolio with Rembra RT and Areta RT CT platforms alongside the helium-free BlueSeal RT 1.5T MR system. These innovations address critical market needs in three dimensions: clinical precision, operational efficiency, and long-term value.
The new CT platforms demonstrate technical superiority with ultra-fast reconstruction speeds of 106 images per second and an extended 85cm field of view - specifications that outperform standard imaging systems. The integration of advanced 4DCT capabilities for respiratory motion management represents a significant clinical advancement for targeting moving tumors in lung, liver, and pancreatic cancers.
What's particularly compelling from an economic perspective is Philips' "Tube for Life Guarantee" and systems designed for 20 years of potential service. X-ray tube replacement typically represents the highest maintenance cost for CT systems, so this guarantee substantially improves the total cost of ownership equation for radiation oncology departments.
The BlueSeal RT MR system continues Philips' leadership in helium-free MR technology with approximately 2,000 such systems already installed globally. The clinical value comes from enhanced soft tissue visualization while the operational value stems from simplified siting requirements (no vent-pipe needed) and lower operating costs. The system's AI-powered SmartSpeed Precise acceleration enabling 10-minute MR-only simulation protocols addresses both the efficiency and patient experience challenges in radiation therapy.
These innovations strengthen Philips' competitive position against GE Healthcare, Siemens Healthineers, and Canon Medical in the radiation oncology imaging market, estimated at
September 26, 2025
- New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value
- Philips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology
Amsterdam, the Netherlands – At the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will introduce groundbreaking additions in radiation oncology: the Philips Rembra RT and Philips Areta RT CT platforms, and the latest helium-free [2] BlueSeal RT 1.5T MR system. Designed to help radiation oncology teams deliver highly accurate, efficient, and patient-centered care, innovative technologies like the new NanoPanel Precise XD detector, built for AI and the AI-based Smartspeed Precise, represent a significant step forward in tackling the growing complexities of radiation therapy planning.
Setting new standards in CT simulation with speed, accuracy, and long-term value
CT imaging is the foundation of precision in radiation therapy planning, delivering accuracy to guide treatment. But as oncology teams face mounting demands for precision, efficiency, and consistency amid staffing and resource pressures, a new era of CT simulation is rising to meet the challenge.
Philips’ new Rembra RT and Areta RT systems are designed to make cancer treatment planning faster and more accurate. These advanced scanners produce clearer, more consistent images so doctors can see tumors in greater detail and plan treatments with confidence. They also save valuable time with ultra-fast image reconstruction speeds up to 106 images per second, and easy-to-use touchscreen gantry controls that help
Beyond imaging, the systems support remote collaboration for planning and training, helping care teams stay connected and efficient without adding extra staff. And with Philips’ industry-first Tube for Life Guarantee and a design for which 20 years of service could be provided (provided commercial upgrades and maintenance), hospitals gain reliable, long-term value while keeping costs lower. Patients also benefit directly, with a high-performance table that allows flexible positioning, faster workflows that shorten waiting times, and shared-use radiology capabilities on Rembra RT to maximize department efficiency.
“Philips invented CT Simulation and introduced the industry’s first Big Bore RT system,” said Dan Xu, Business Leader of CT at Philips. “With Rembra RT and Areta RT, we’re once again setting new standards in radiation therapy, empowering care teams with the precision, dependability, and speed they need to deliver the best outcomes for patients.”
Philips is also currently working with MVision AI to explore opportunities to include MVision AI’s Contour+ AI-powered auto-segmentation software with Philips CT simulators, including the new Rembra RT and Areta RT systems. Contour+ delivers fast and precise automatic delineation of organs at risk and lymph node areas.
Philips expands MR leadership with helium-free BlueSeal RT [4]
Alongside its newest CT innovations, Philips is introducing BlueSeal MR RT in North America [5], the company’s latest helium-free [2] 1.5T 70cm MR system designed for radiation oncology. Powered by AI-based SmartSpeed Precise acceleration software, BlueSeal RT enables enhanced simulation confidence.
MR plays an increasingly vital role in radiation therapy, enabling clinicians to visualize tumors and surrounding healthy tissue with far greater detail, which is essential for planning precise treatments. By combining sustainability with advanced imaging, BlueSeal RT transforms therapy planning with enhanced simulation confidence, reducing registration errors to help protect healthy organs. In addition, MR-only imaging with MRCAT simplifies workflows. With full MR-only simulation protocols in as little as 10 minutes, patients also benefit, experiencing shorter scans that improve comfort and overall experience, especially for those wearing a mask.
With approximately 2,000 helium-free [2] MR scanners installed worldwide, Philips is driving the shift to sustainable MR. BlueSeal RT extends this leadership into radiotherapy by addressing a key challenge for oncology departments: installing MR systems in complex clinical environments such as Radiation Oncology departments. Its light-weight, vent-pipe-free design opens new siting possibilities - whether in basements, bunkers, or higher floors - while also lowering cost and energy use through helium-free [2] operation and PowerSave+ efficiency.
“BlueSeal RT is leading the way in MR for radiotherapy,” said Ioannis Panagiotelis, PhD, Business Leader MR at Philips. “By combining helium-free [2] sustainability with AI-powered acceleration, we’re enabling radiation oncology teams to plan and simulate with greater speed, accuracy, and confidence—while enhancing the patient experience.”
“Radiation oncology teams need transformative innovation to meet today’s accuracy, workflow, and cost challenges,” said Christopher M. Freese, MD, The Christ Hospital. “With Rembra RT, Areta RT, and BlueSeal RT, Philips is setting new standards for precision and efficiency in radiation therapy across CT and MR.”
For more information, visit Philips at ASTRO 2025.
[1] 510(k) pending. Not available for sale in the US.
[2] 7 liters of helium are permanently enclosed in the cryogenic circuit.
[3] Based on a third-party survey of 145 users across eight countries. Quantitative Report 2020 Incisive CT. The MarketTech Group. November, 2020. Actual results in other cases may vary.
[4] BlueSeal RT is a configuration of BlueSeal XE/SE.
[5] BlueSeal RT is an add-on to the existing Ingenia 1.5T and 3.0T MR systems that makes the system suitable for MR imaging for radiation therapy planning purposes. BlueSeal RT consists of RTGo SW and MR CouchTop accessory. RTgo is a software that provides MR-RT functionality including MRCAT (MRCAT Prostate, MRCAT Pelvis, MRCAT Brain, MRCAT Head &Neck)
For further information, please contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Philips news RembraRT CT Platform - 01
- Philips news RembraRT CT Platform - 02
- Philips BlueSeal MR RT in use - 01
- Philips BlueSeal MR RT in use - 02
FAQ
What new radiation therapy technologies did Philips (PHG) announce at ASTRO 2025?
What are the key features of Philips' new Rembra RT and Areta RT CT platforms?
How does the new Philips BlueSeal RT MR system improve radiation therapy planning?
What cost benefits do the new Philips radiation therapy systems offer?
When will Philips' new Rembra RT and Areta RT platforms be available in the US?
